Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SPECT/CT Imaging of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Primary Tumour and Metastatic Axillary Lymph Nodes Using Technetium-99m-labelled DARPinG3 Molecule-based.

NCT05695859 is registered in ClinicalTrials.gov with Tomsk National Research Medical Center of the Russian Academy of Sciences as lead sponsor.

NCT NCT05695859
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05695859 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SPECT/CT Imaging of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Primary Tumour and Metastatic Axillary Lymph Nodes Using Technetium-99m-labelled DARPinG3 Molecule-based.
Lead sponsor
Tomsk National Research Medical Center of the Russian Academy of Sciences
Phase
Observational
Overall status
Completed
Start date
December 20, 2022
Completion date
December 1, 2023
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer female